Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Myeloid Therapeutics
Novartis
Nurix Therapeutics, Inc.
Xencor, Inc.
Context Therapeutics Inc.
Lyell Immunopharma, Inc.
Theratechnologies
Exelixis
Carisma Therapeutics Inc
Hoffmann-La Roche
Eli Lilly and Company
Instil Bio
BioEclipse Therapeutics
Multitude Therapeutics Inc.
Canadian Cancer Trials Group
Xencor, Inc.
MacroGenics
AIDS Malignancy Consortium
Abramson Cancer Center at Penn Medicine
Canadian Cancer Trials Group
University of Washington
Pfizer
National Cancer Institute (NCI)
University of Washington
University of Southern California
NewVac LLC
University of Arizona
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Washington
University of California, San Francisco
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
University of Alabama at Birmingham
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Cancer Research UK
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
AstraZeneca